Zurück zur Übersicht
| Cancer discovery. 2018 May 30. pii: 2159-8290.CD-18-0229. doi: 10.1158/2159-8290.CD-18-0229 |
| Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. |
| Pal SK1, Rosenberg JE2, Hoffman-Censits JH3, Berger R4, Quinn DI5, Galsky MD6, Wolf J7, Dittrich C8, Keam B9, Delord JP10, Schellens JHM11, Gravis G12, Medioni J13, Maroto P14, Sriuranpong V15, Charoentum C16, Burris HA17, Grünwald V18, Petrylak D19, Vaishampayan U20, Gez E21, De Giorgi U22, Lee JL23, Voortman J24, Gupta S25, Mortazavi A26, Vaughn DJ27, Isaacs RE28, Parker K29, Chen X30, Yu K31, Porter D32, Sharma S33, Graus Porta D34, Bajorin DF35 |
 Author information
|
|
Abstract BGJ398, a potent and selective pan-fibroblast growth factor receptor (FGFR) antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation and decreased appetite. Further examination of BGJ398 in this disease setting is warranted. |
|
Copyright ©2018, American Association for Cancer Research. |
|
Publikations ID: 29848605 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
